Eli Lilly's Rajiv Gulati on Prospects in India and China
Episode Description
India's huge potential pharmaceutical market and wealth of industry talent means it will be strategically critical for multinationals in the years ahead, notes Rajiv Gulati, director of India-China strategy and corporate strategic planning for Eli Lilly. But weak intellectual property protection continues to hold the country back by hampering innovation, he says. In China, there may be even greater potential, but huge regulatory barriers block a clear path. Gulati spoke with India Knowledge@Wharton about these and other industry issues during the 2008 Wharton India Economic Forum.
Brief Summary
Rajiv Gulati discusses Eli Lilly's strategies in India and China, joint ventures, and access to medicines in the pharmaceutical industry.
Key points
- Eli Lilly's Market Strategies. Eli Lilly adapts its strategies for China and India, focusing on local strengths.
- Challenges in Indian Pharmaceutical Market. Over 60% of India's population lacks access to medicines despite low prices.
Ask about Knowledge at Wharton
Episode highlights
- Eli Lilly's Market StrategiesEli Lilly adapts its strategies for China and India, focusing on local strengths.“India has much more to offer because of their local industry strength.”6:44Oct 16, 2008
- Challenges in Indian Pharmaceutical MarketOver 60% of India's population lacks access to medicines despite low prices.“60 to 70% of the population in India does not have access to medicines.”10:10Oct 16, 2008
Tension
45/ 100Some tension
